Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis( )

AIMS: Targeting vascular inflammation represents a novel therapeutic approach to reduce complications of atherosclerosis. Neutralizing the pro-inflammatory cytokine interleukin-1β (IL-1β) using canakinumab, a monoclonal antibody, reduces the incidence of cardiovascular events in patients after myoca...

Descripción completa

Detalles Bibliográficos
Autores principales: Hettwer, Jan, Hinterdobler, Julia, Miritsch, Benedikt, Deutsch, Marcus-André, Li, Xinghai, Mauersberger, Carina, Moggio, Aldo, Braster, Quinte, Gram, Hermann, Robertson, Avril A B, Cooper, Matthew A, Groß, Olaf, Krane, Markus, Weber, Christian, Koenig, Wolfgang, Soehnlein, Oliver, Adamstein, Nicholas H, Ridker, Paul, Schunkert, Heribert, Libby, Peter, Kessler, Thorsten, Sager, Hendrik B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586563/
https://www.ncbi.nlm.nih.gov/pubmed/34718444
http://dx.doi.org/10.1093/cvr/cvab337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586563/
https://www.ncbi.nlm.nih.gov/pubmed/34718444
http://dx.doi.org/10.1093/cvr/cvab337

Ejemplares similares